Board of Directors

James M. Hindman has served as a member of our Board since September 2019. Mr. Hindman had served in various positions at Allergan, Inc. (“Allergan”), a multi-specialty healthcare company, from 1984 to March 2015, where he held positions of increasing responsibility, including most recently as the Executive Vice President and Chief Financial Officer of Allergan from August 2014 to March 2015. Mr. Hindman served as Senior Vice President of Treasury, Risk and Investor Relations from March 2002 to August 2014, and, from 1984 to 2002, Mr. Hindman served a variety of other finance positions at Allergan, including Senior Vice President, Finance and Controller; Vice President, Finance; Vice President, Financial Planning and Analysis; and Assistant Corporate Controller. Mr. Hindman currently serves on the board of Urovant Sciences, Inc., Aatru Medical, and Amolyt Pharma SAS. He has also provided financial consulting services to Cidara Therapeutics, Inc., a public biotechnology company, since July 2015, and to RANI Therapeutics, a privately held biotechnology company, from December 2017 to December 2018. Mr. Hindman currently serves as a member of the Board of Regents at Loyola Marymount University and serves as a member of the Dean’s Executive Council for the College of Business Administration at Loyola Marymount University. Mr. Hindman holds a B.S. in Accounting from Loyola Marymount University and a M.B.A. from Pepperdine University. He is a Certified Public Accountant in the state of California (inactive).

Class III Director, Term Expires 2024

Beverly Huss has served as a member of our Board of Directors since January 2018. Since 2021, she has served as Chief Executive Officer of Pagonia Medical, Inc., a private company focused on creating a novel non-invasive device for the preservation of tissue following a heart attack, stroke, traumatic brain injury and other medical conditions.  Prior to Pagonia, Ms. Huss served as President and Chief Executive Officer of Qool Therapeutics, Inc., formerly Thermocure, Inc., a privately held development stage company focused on temperature management therapies. Prior to joining Qool, Ms. Huss was President and Chief Executive Officer at start-up medical device company Vibrynt, Inc., and held multiple senior level leadership positions at Guidant Corporation, including, most recently President, Endovascular Solutions, and Vice President, Global Marketing, Vascular Intervention and Vice President of the Stent Business Unit.

Ms. Huss also currently serves on the boards of Pagonia Medical, Inc. and Madorra Inc. Her prior public company board experience includes Artes Medical, Wright Medical Group, and Dade Behring, Inc.

Class II Director, Term Expires 2026

Robert C. Kill has served as a member of our Board of Directors since January 2023. He is currently an Executive in Residence for Frazier Healthcare Partners, a leading private equity firm focused exclusively on the healthcare industry. From 2017 to 2022, Mr. Kill served as CEO of Frazier portfolio company Parata Systems, a pharmacy automation technology provider serving hospital, retail, long term care, mail order and government pharmacies. From 2016 to 2022, Mr. Kill also served as a board member of Ascension Ventures, a strategic healthcare venture capital fund. Prior to joining Frazier as an Executive in Residence in 2016, Mr. Kill served as Chairman and CEO of Cogentix Medical Inc., a high growth global medical device company, and as Chairman and CEO of Virtual Radiologic Corporation, a provider of technology-enabled outsourced radiology solutions. He also was President of Misys Physician Systems, a developer of electronic medical record and practice management software applications. He began his career at Baxter Healthcare and holds a B.A. in Economics from the University of Notre Dame. 

Class I Director, Term Expires 2025

Anne B. Le Grand has served as a member of our Board since July 2020. Ms. Le Grand has served as a consultant to IBM Watson Health, a machine intelligence company that is a division of the International Business Machines Corporation (“IBM”), an information technology company, since January 2021. Prior to that, Ms. Le Grand also served as Vice President and General Manager of Imaging, Life Sciences, Oncology and Genomics at IBM Watson Health from July 2019 to December 2020 and VP and General Manager of Imaging at IBM Watson Health from April 2016 to July 2019. Prior to her roles at IBM Watson Health, Ms. Le Grand served as Senior Vice President of Healthcare and General manager of Therapeutics from January 2015 to April 2016 and Senior Vice President of Healthcare Business Transformation from January 2014 to January 2015 at Philips, a health technology company. Ms. Le Grand previously served in various senior leadership positions at GE Healthcare and Eastman Kodak Company and began her career at 3M Company in the Medical Imaging Division. Ms. Le Grand holds a B.S. in Chemistry from Queens University of Charlotte.

Class I Director, Term Expires 2025

Mika Nishimura has served as a member of our Board since August 2021.  Since 2011, Ms. Nishimura has served as an Operational Partner with Gilde Healthcare Partners, a life-science focused venture fund. She also serves as a board member of SI-BONE, Inc., a public medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, and as a board advisor to Tristel, plc, a UK public medical technology company. From 2015 to 2020, Ms. Nishimura served as Vice President of Commercialization at nVision Medical Corporation, an early clinical-stage medical device company acquired by Boston Scientific. Previously, she served as Vice President, Commercial Development at Auxogyn Incorporated, a medical technology company, acquired by Progyny, Inc. Earlier in her career, Ms. Nishimura served as Vice President of International Sales Operations and Marketing at ev3 Incorporated, where she held P&L responsibilities for the emerging markets. Ms. Nishimura has an MBA from Harvard Graduate School of Business Administration and a B.A. in Economics from Yale University.

Class II Director, Term Expires 2026

Byron C. Scott has served as a member of our Board since February 2021.  Dr. Scott has served as the Chief Operating Officer at Direct Relief, a humanitarian medical aid and disaster relief organization, since January 2024, where he was previously on the Board of Directors.  Dr. Scott has served as Adjunct Faculty at the University of Massachusetts, Amherst, Isenberg School of Management since 2016 and Adjunct Faculty at Thomas Jefferson University, Jefferson College of Population Health since 2019 where he teaches healthcare quality, patient safety, and performance improvement.  Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from 2017 to 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership.  Dr. Scott served at Truven Health Analytics, which was acquired by IBM in 2016, from 2014 to 2017, most recently as Associate Chief Medical Officer from 2015 to 2017.  Dr. Scott previously served at EmCare, a hospital-based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the West Division from 2011 to 2013.

Dr. Scott is board certified in emergency medicine and previously practiced medicine for over 25 years. He serves as a member of the Board of Directors of Providence Health Plan and serves as a Board Trustee at Rady Children’s Hospital-San Diego.  Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachusetts, Amherst, Isenberg School of Management.  He is Directorship Certified by the National Association for Corporate Directors (NACD) and holds a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD.

Class II Director, Term Expires 2026

Joseph E. Whitters has served as a member of our Board of Directors since July 2018 and Chairperson of our Board since January 2021. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in various capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previously served as the Controller for United Healthcare Corp. from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Mr. Whitters currently serves as a member of the board of directors of Cutera Inc. and Spark Networks SE. Previously, Mr. Whitters served on the boards of directors and audit committees of various public companies, including Analogic Corporation, InfuSystem Holdings, Inc. and PRGX Global, Inc.. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College.

Class I Director, Term Expires 2025 

Suzanne Winter is the President and CEO of Accuray, bringing more than 30 years of healthcare med tech experience. She joined Accuray as Senior Vice President, Chief Commercial Officer in October 2019. Prior to joining Accuray, Suzanne held senior executive roles spanning general management, commercial and business development across a range of healthcare industry segments, including diagnostic imaging, cardiovascular, neurocritical care and surgery. Most recently, she served as Group Vice President Medtronic Diabetes where she was responsible for $1.4B Americas region leading a 2,000-person commercial organization. Before Medtronic, Suzanne was the General Manager of GE Healthcare’s Interventional, X-ray and Mammography business.

Suzanne earned a Master of Business Administration degree from Harvard University Graduate School of Business in Boston, Massachusetts and a Bachelor of Science degree with a specialization in chemistry from Saint Lawrence University in Canton, New York.

Class III Director, Term Expires 2024